✦ LIBER ✦

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

✍ Scribed by Sandro Pignata; Giovanni Scambia; Antonella Savarese; Enrico Breda; Paolo Scollo; Rocco De Vivo; Emanuela Rossi; Vittorio Gebbia; Donato Natale; Filomena Del Gaizo; Emanuele Naglieri; Antonella Ferro; Pietro Musso; Alfonso Maria D'Arco; Roberto Sorio; Carmela Pisano; Massimo Di Maio; Giuseppe Signoriello; Annalisa Annunziata; Francesco Perrone; the MITO Investigators (see appendix)

Book ID: 115010843
Publisher: BioMed Central
Year: 2006
Tongue: English
Weight: 247 KB
Volume: 6
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-6-202

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase III study comparing p

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

✍ Smorenburg, C. H.; de Groot, S. M.; van Leeuwen-Stok, A. E.; Hamaker, M. E.; Wym 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 218 KB

Carboplatin plus gemcitabine as first-li

Carboplatin plus gemcitabine as first-line treatment in eldelry patients with non-small-cell lung cancer: Preliminary results of a multicenter phase ii trial by the Hellenic Oncology Researsch Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Kentepozidis, N.; Polyzos, A.; Kotsa 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 48 KB